Financiado en parte por Vifor Pharma
Omega-3 polyunsaturated fatty acid supplementation and cognition: A systematic review and meta-analysis
Cooper RE, Tye C, Kuntsi J, Vassos E, Asherson P
Journal of psychopharmacology (Oxford, England) · 84 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Vifor Pharma
- Universidad u hospital
- Menzies Centre for Australian Studies, King's College London, University of London
Según 2 financiadores declarados.
Publicación
- Publicado
- 2015-06-03 · J Psychopharmacol · vol. 29 · número 7 · págs. 753–763
- Editorial
- SAGE Publishing
- Citado
- 108 citas · más que el 85% de estudios similares · 1.8× el promedio de su campo
- Referencias
- 68 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Aquaculture Nutrition and Growth · Attention Deficit Hyperactivity Disorder
- Palabras clave
- omega-3 polyunsaturated fatty acids, dietary supplementation, cognition, attention deficit hyperactivity disorder, neurodevelopmental disorders, short-term memory, school-aged children, adults
- MeSH
- humans, fatty acids, omega-3, cognition, memory, short-term, attention deficit disorder with hyperactivity, dietary supplements, adult, child, randomized controlled trials as topic
5 autores
- Ruth E Cooper🇬🇧King's College London
- Charlotte Tye🇬🇧King's College London
- Jonna Kuntsi🇬🇧King's College London
- Evangelos Vassos🇬🇧King's College London
- Philip J. Asherson🇬🇧King's College London
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Omega-3 polyunsaturated fatty acids (n-3 PUFAs) are promoted as cognitive enhancers with consumption recommended in the general population and those with neurocognitive deficits such as attention deficit hyperactivity disorder (ADHD). However, evidence from randomised placebo-controlled trials is inconclusive.
Aims
This study aimed to conduct a systematic review and meta-analysis examining the effect of n-3 PUFA supplementation on cognition in healthy populations and those with ADHD and related disorders (RDs).
Methods
Databases were searched for randomised controlled trials (RCTs) in adults and school-aged children (who were healthy and typically developing (TD) or had ADHD or a related-neurodevelopmental disorder (ADHD+RD) which assessed the effects of n-3 PUFA on cognition.
Results
In the 24 included studies n-3 PUFA supplementation, in the whole sample and the TD and ADHD+RD subgroup, did not show improvements in any of the cognitive performance measures. In those with low n-3 PUFA status, supplementation improved short-term memory.
Conclusions
There is marginal evidence that n-3 PUFA supplementation effects cognition in those who are n-3 PUFA deficient. However, there is no evidence of an effect in the general population or those with neurodevelopmental disorders. This has important implications given the widespread advertisement and consumption of n-3 PUFA; claims of cognitive benefit should be narrowed.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.